Fordyce Marshall 4
4 · Vera Therapeutics, Inc. · Filed Feb 27, 2025
Insider Transaction Report
Form 4
Fordyce Marshall
DirectorPRESIDENT AND CEO
Transactions
- Sale
Class A Common Stock
2025-02-26$27.55/sh−7,975$219,732→ 205,765 total - Sale
Class A Common Stock
2025-02-21$27.89/sh−10,613$296,032→ 213,740 total - Sale
Class A Common Stock
2025-02-26$28.32/sh−1,100$31,150→ 204,665 total
Holdings
- 222,030(indirect: By GRAT)
Class A Common Stock
Footnotes (7)
- [F1]The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of three (3) business days, beginning on February 21, 2025 and ending on February 25, 2025.
- [F2]Pursuant to Rule 16a-3(g)(2) and (3).
- [F3]Shares sold to cover tax withholding obligations associated with the vesting of RSUs pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on August 26, 2022.
- [F4]The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.37 to $29.80, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F5]The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024.
- [F6]The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.24 to $28.21, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F7]The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.25 to $28.42, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.